HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo

HIV Non-Nucleoside Reverse Transcriptase Inhibitor Efavirenz Reduces Neural Stem Cell Proliferation in Vitro and in Vivo

The prevalence of HIV-associated neurocognitive disorders (HAND) remains high despite combination antiretroviral therapy (cART). There is evidence that neural stem cells (NSCs) can migrate to sites of brain injury such as those caused by inflammation and oxidative stress, which are pathological feat...

Full description

Bibliographic Details
Main Authors:	Jingji Jin, Bethany Grimmig, James Izzo, Lecia A. M. Brown, Charles Hudson, Adam J. Smith, Jun Tan, Paula C. Bickford, Brian Giunta
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-11-01
Series:	Cell Transplantation
Online Access:	https://doi.org/10.3727/096368916X691457

Similar Items

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
by: Mastan SK, et al.
Published: (2009-10-01)

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
by: Markus Hecht, et al.
Published: (2015-01-01)

Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
by: Smita Prakash Kakad, et al.
Published: (2021-01-01)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz
by: Maryam A. Jordaan, et al.
Published: (2020-08-01)

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
by: Esnouf, R, et al.
Published: (1995)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
by: Murugesan Vanangamudi, et al.
Published: (2023-09-01)

Current scenario on non-nucleoside reverse transcriptase inhibitors (2018-present)
by: Cui Deng, et al.
Published: (2022-12-01)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
by: N. S. Shastina, et al.
Published: (2011-04-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Valeria Famiglini, et al.
Published: (2016-02-01)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
by: Daniel M. Himmel, et al.
Published: (2020-06-01)

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors
by: Nicolas Tardiota, et al.
Published: (2024-01-01)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
by: Lívia da Rocha Fernandes, et al.
Published: (2023-11-01)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
by: Anna Stachowicz-Kuśnierz, et al.
Published: (2023-08-01)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance.
by: Meytal Galilee, et al.
Published: (2018-01-01)

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study
by: A. V. Kravchenko, et al.
Published: (2018-07-01)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
by: Bonté Frédéric, et al.
Published: (2009-09-01)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
by: Chan, J, et al.
Published: (2001)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
by: Ren, J, et al.
Published: (2008)

Global Conformational Dynamics of HIV-1 Reverse Transcriptase Bound to Non-Nucleoside Inhibitors
by: Peter V. Coveney, et al.
Published: (2012-07-01)

Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
by: Chunlin Zhuang, et al.
Published: (2020-06-01)

Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors
by: Nicolas Sluis-Cremer, et al.
Published: (2013-11-01)

Nucleoside analogue reverse transcriptase inhibitors differentially inhibit human LINE-1 retrotransposition.
by: R Brad Jones, et al.
Published: (2008-01-01)

In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs.
by: Kyle R Hukezalie, et al.
Published: (2012-01-01)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
by: Tanaka, H, et al.
Published: (1999)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
by: Pelemans, H, et al.
Published: (1998)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
by: Milton, J, et al.
Published: (1998)

Exploring QSAR of non-nucleoside reverse transcriptase inhibitors by artificial neural networks: HEPT derivatives
by: Mohamed Zahouily, et al.
Published: (2007-09-01)

Novel Thiazolidin-4-ones as Potential Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
by: Anthi Petrou, et al.
Published: (2019-10-01)

APOBEC3 selects V179I in HIV-1 reverse transcriptase to provide selective advantage for non-nucleoside reverse transcriptase inhibitor-resistant mutants
by: Richa Dwivedi, et al.
Published: (2022-07-01)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
by: Freeman, G, et al.
Published: (2004)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
by: Hopkins, A, et al.
Published: (2004)

Identification of Boronate-Containing Diarylpyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
by: Da Feng, et al.
Published: (2022-11-01)

Modeling of cytotoxicity on some non- nucleoside reverse transcriptase inhibitors of HIV-1: role of physicochemical parameters
by: B.K. Tiwari, et al.
Published: (2006-02-01)

Nucleoside reverse transcriptase inhibitors and Kamuvudines inhibit amyloid-β induced retinal pigmented epithelium degeneration
by: Siddharth Narendran, et al.
Published: (2021-04-01)

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
by: Alexandra U Scherrer, et al.
Published: (2012-01-01)

Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
by: Lecia A M Brown, et al.
Published: (2014-01-01)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
by: Ren, J, et al.
Published: (2000)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
by: Ren, J, et al.
Published: (2002)

Molecular docking analysis of novel Non-Nucleoside Reverse Transcriptase Inhibitors in development: implication for rational drug design
by: Singh Ramendra K, et al.
Published: (2011-10-01)